Sayali Mukherjee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sayali Mukherjee has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Yadvendra Shahi
Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow Campus, Uttar Pradesh, India; Ram Manohar Lohia Institute of Medical Sciences (RMLIMS), Lucknow, Uttar Pradesh, India
4 shared publicationsTooba Qamar
Sanjay Gandhi Post Graduate Institute of Medical Sciences (SGPGIMS)
3 shared publicationsDivya Prasad
Amity Univ Uttar Pradesh, Amity Inst Biotechnol, Lucknow Campus, Lucknow 226028, Uttar Pradesh, India
2 shared publicationsFahad M. Samadi
Department of Oral Pathology, King George Medical University, Lucknow, India
2 shared publicationsShatakshi Narang
Amity Institute of Biotechnology, Amity University Uttar Pradesh Lucknow Campus, Lucknow, India
2 shared publicationsStuti Maurya
University of Glasgow
2 shared publications
Latest Publications
- 12 August 2026
- Published by Springer Nature in Cell Biochemistry and Biophysics
- p. 1-17
Ferroptosis–Inflammation Crosstalk: Mechanistic Insights and Emerging Drug Targets
- 12 August 2026
- Published by Springer Nature in Cell Biochemistry and Biophysics
- p. 1-17
Ferroptosis–Inflammation Crosstalk: Mechanistic Insights and Emerging Drug Targets
- 1 October 2025
- Published by Springer Nature
- p. 243-266
Bone Infections: Associations with Bacterial Biofilm
- 1 October 2025
- Published by Springer Nature
- p. 243-266
Bone Infections: Associations with Bacterial Biofilm
- 4 August 2025
- Published by Springer Nature in Regenerative Engineering and Translational Medicine
- Vol. 12 (3) , 1-21
A Review on 4D Tissue Bioprinting: New Dawn for Tissue Engineering
- 4 August 2025
- Published by Springer Nature in Regenerative Engineering and Translational Medicine
- Vol. 12 (3) , 1-21
A Review on 4D Tissue Bioprinting: New Dawn for Tissue Engineering
- 23 July 2025
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 39 (8) , e70403
Epigenetic Regulation and Targeted Therapy in Gall Bladder Cancer
Gall bladder cancer is a formidable malignancy known for its aggressive nature and often late‐stage diagnosis. In recent years, oncology has changed basic assumptions towards personalized and targeted therapies. Significant emphasis has been paid to research and clinical contexts about DNA methylation, histone changes, and microRNA alterations as key epigenetic pathways linked to the development of gall bladder cancer. The review delves into the potential of epigenetic markers as diagnostic and prognostic tools and discusses their utility in finding novel therapeutic targets. Targeted therapies have demonstrated effectiveness in addressing various types of cancer, and gall bladder cancer is no exception. The recent advancements in targeted therapies tailored for gall bladder cancer have been elaborated, underscoring the vital role of precision medicine in customizing treatment plans to suit individual patients. The review also examines the challenges and opportunities associated with the development of therapies specifically designed to target epigenetic changes, potentially offering treatment options that are both more efficacious and less toxic.
- 23 July 2025
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 39 (8) , e70403
Epigenetic Regulation and Targeted Therapy in Gall Bladder Cancer
Gall bladder cancer is a formidable malignancy known for its aggressive nature and often late‐stage diagnosis. In recent years, oncology has changed basic assumptions towards personalized and targeted therapies. Significant emphasis has been paid to research and clinical contexts about DNA methylation, histone changes, and microRNA alterations as key epigenetic pathways linked to the development of gall bladder cancer. The review delves into the potential of epigenetic markers as diagnostic and prognostic tools and discusses their utility in finding novel therapeutic targets. Targeted therapies have demonstrated effectiveness in addressing various types of cancer, and gall bladder cancer is no exception. The recent advancements in targeted therapies tailored for gall bladder cancer have been elaborated, underscoring the vital role of precision medicine in customizing treatment plans to suit individual patients. The review also examines the challenges and opportunities associated with the development of therapies specifically designed to target epigenetic changes, potentially offering treatment options that are both more efficacious and less toxic.
- 3 July 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 52 (1) , 1-22
Pathophysiology of spinal cord injury and advanced therapeutic approaches
Spinal cord injuries are severe and debilitating, potentially causing permanent neurological losses. Such devastating injuries are associated with limitations in the established treatments, thus demanding some innovative avenues. One among such highly promising approaches concerning tissue-engineered repair in spinal cord injuries (SCI) is the employment of an amalgamation of cells, growth factors, and scaffolds by considering their possible application for regeneration and repair in damaged tissues. This review article covers all the complex pathophysiology associated with SCI, including acute, subacute, intermediate, and chronic phases. Traditional treatments include medications, surgery, and rehabilitation while advanced tissue engineering approaches involve hydrogels as well as electro spun nanofibers as cell scaffolds. Stem cells applied in such therapies may be derived from dental pulp stem cells, stromal cells, oral mucosa stem cells and olfactory ensheathing cells. Regeneration of the damaged area is dictated by controlling factors like neurotrophic factors, cyclic AMP, chondroitin sulphate, inflammatory cytokines etc. 3D scaffolds are recommended over 2D scaffolds. A dynamic and more effective method is provided by 4D scaffolds which may alter the structure in response to inputs. While there have been groundbreaking developments with these approaches, significant challenges exist in the translation of these laboratory investigations into efficacious therapies in the clinical setting. Further studies are thus needed to optimize the sources of cells, scaffold design, and delivery methods to attain the highest possible outcomes. The review also focuses on extracellular vesicular therapies and targeted therapies hold more promise for effective recovery.
- 3 July 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 52 (1) , 1-22
Pathophysiology of spinal cord injury and advanced therapeutic approaches
Spinal cord injuries are severe and debilitating, potentially causing permanent neurological losses. Such devastating injuries are associated with limitations in the established treatments, thus demanding some innovative avenues. One among such highly promising approaches concerning tissue-engineered repair in spinal cord injuries (SCI) is the employment of an amalgamation of cells, growth factors, and scaffolds by considering their possible application for regeneration and repair in damaged tissues. This review article covers all the complex pathophysiology associated with SCI, including acute, subacute, intermediate, and chronic phases. Traditional treatments include medications, surgery, and rehabilitation while advanced tissue engineering approaches involve hydrogels as well as electro spun nanofibers as cell scaffolds. Stem cells applied in such therapies may be derived from dental pulp stem cells, stromal cells, oral mucosa stem cells and olfactory ensheathing cells. Regeneration of the damaged area is dictated by controlling factors like neurotrophic factors, cyclic AMP, chondroitin sulphate, inflammatory cytokines etc. 3D scaffolds are recommended over 2D scaffolds. A dynamic and more effective method is provided by 4D scaffolds which may alter the structure in response to inputs. While there have been groundbreaking developments with these approaches, significant challenges exist in the translation of these laboratory investigations into efficacious therapies in the clinical setting. Further studies are thus needed to optimize the sources of cells, scaffold design, and delivery methods to attain the highest possible outcomes. The review also focuses on extracellular vesicular therapies and targeted therapies hold more promise for effective recovery.
- 4 April 2025
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1869 (6) , 130800
Inhibitors of inflammasome (NLRP3) signaling pathway as promising therapeutic candidates for oral cancer
- 4 April 2025
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1869 (6) , 130800
Inhibitors of inflammasome (NLRP3) signaling pathway as promising therapeutic candidates for oral cancer
- 22 December 2024
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 126 (2) , e30690
MicroRNAs as Biomarker in Rheumatoid Arthritis: Pathogenesis to Clinical Relevance
MicroRNAs (miRNAs) have emerged as intricate players in rheumatoid arthritis (RA), holding promise as discerning biomarkers for diagnostic and prognostic purposes. The lack of sensitivity and specificity in current diagnostic techniques, such as rheumatoid factor (RF) and anti‐citrullinated protein antibodies (ACPA), causes diagnosis delays in RA. The miR‐146a and miR‐155 act in inflammatory cascades and reduce joint deterioration, and miR‐223 is paradoxical, acting differently in different illness scenarios. The microenvironment of RA is shaped by the complex modulation of gene expression and cytokine dynamics by miR‐126 and miR‐24. miRNAs serve as a promising candidate for precision medicine in the management of RA. There are obstacles encountered in validation, delivery optimization, and off‐target effect mitigation before miRNA‐based biomarkers may be applied in clinical settings. Machine learning (ML) and artificial intelligence (AI) have been used to integrate miRNA expression patterns with clinical data to greatly advance the treatment of RA. Because of the disease's inherent complexity and variability, these state‐of‐the‐art models provide accurate predictions regarding the onset, development, and response to treatment of RA. By using clinical information and miRNA expression data, ML algorithms are revolutionizing the treatment of RA by predicting the onset and course of the disease with remarkably high accuracy. The development of therapeutic modalities and miRNA profiling has great potential to transform the diagnosis, prognosis, and treatment of RA, providing fresh hope for better patient outcomes.
- 22 December 2024
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 126 (2) , e30690
MicroRNAs as Biomarker in Rheumatoid Arthritis: Pathogenesis to Clinical Relevance
MicroRNAs (miRNAs) have emerged as intricate players in rheumatoid arthritis (RA), holding promise as discerning biomarkers for diagnostic and prognostic purposes. The lack of sensitivity and specificity in current diagnostic techniques, such as rheumatoid factor (RF) and anti‐citrullinated protein antibodies (ACPA), causes diagnosis delays in RA. The miR‐146a and miR‐155 act in inflammatory cascades and reduce joint deterioration, and miR‐223 is paradoxical, acting differently in different illness scenarios. The microenvironment of RA is shaped by the complex modulation of gene expression and cytokine dynamics by miR‐126 and miR‐24. miRNAs serve as a promising candidate for precision medicine in the management of RA. There are obstacles encountered in validation, delivery optimization, and off‐target effect mitigation before miRNA‐based biomarkers may be applied in clinical settings. Machine learning (ML) and artificial intelligence (AI) have been used to integrate miRNA expression patterns with clinical data to greatly advance the treatment of RA. Because of the disease's inherent complexity and variability, these state‐of‐the‐art models provide accurate predictions regarding the onset, development, and response to treatment of RA. By using clinical information and miRNA expression data, ML algorithms are revolutionizing the treatment of RA by predicting the onset and course of the disease with remarkably high accuracy. The development of therapeutic modalities and miRNA profiling has great potential to transform the diagnosis, prognosis, and treatment of RA, providing fresh hope for better patient outcomes.
- 2 September 2024
- Published by Elsevier in Gene Reports
- Vol. 37
Genetic variants of interleukin-1α, interleukin-12β and matrix metalloproteinase-9 in oral cancer risk and progression
- 2 September 2024
- Published by Elsevier in Gene Reports
- Vol. 37
Genetic variants of interleukin-1α, interleukin-12β and matrix metalloproteinase-9 in oral cancer risk and progression
- 1 June 2024
- Published by Bentham Science Publishers Ltd. in Current Gene Therapy
- Vol. 24 (3) , 179-192
Therapeutic Potential of CRISPR/Cas in Hashimoto's Thyroiditis: A Comprehensive Review
Hashimoto’s thyroiditis (HT) is a commonly occurring illness of autoimmune endocrine origin. It is usually present in the pediatric age group along with other well-known diseases, such as type 1 insulin-dependent diabetes. The defining feature of this disease is the immune-- mediated attack on the thyroid gland resulting in the destruction of thyroid tissues and cells. Given that HT frequently affects family members, it is well-recognized that individuals are genetically predisposed to this disease. Patients with HT also display a significantly increased risk for several different cancers, justifying the eminent need for the development of therapies for managing and treating HT. Gene editing has made several advancements in the field of molecular biology and has turned out to become a promising approach to correct several autoimmune diseases. Currently, CRISPR/Cas, a nuclease-based editing technique, is publicized as a promising tool for curing several genetic diseases and cancers. However, very limited research has been conducted as of now on autoimmune disease management and cure via CRISPR/Cas technique. This review provides an account of the potential candidate genes associated with Hashimoto’s thyroiditis, and only a few animal and human models have been generated via the CRISPR/Cas gene editing technique. Mouse models of autoimmune thyroiditis generated through the CRISPR/Cas gene editing technique by targeting the candidate genes will provide us with a deeper insight into the pathophysiology of HT and further pave the way for the immunomodulation of HT via gene editing.
- 1 June 2024
- Published by Bentham Science Publishers Ltd. in Current Gene Therapy
- Vol. 24 (3) , 179-192
Therapeutic Potential of CRISPR/Cas in Hashimoto's Thyroiditis: A Comprehensive Review
Hashimoto’s thyroiditis (HT) is a commonly occurring illness of autoimmune endocrine origin. It is usually present in the pediatric age group along with other well-known diseases, such as type 1 insulin-dependent diabetes. The defining feature of this disease is the immune-- mediated attack on the thyroid gland resulting in the destruction of thyroid tissues and cells. Given that HT frequently affects family members, it is well-recognized that individuals are genetically predisposed to this disease. Patients with HT also display a significantly increased risk for several different cancers, justifying the eminent need for the development of therapies for managing and treating HT. Gene editing has made several advancements in the field of molecular biology and has turned out to become a promising approach to correct several autoimmune diseases. Currently, CRISPR/Cas, a nuclease-based editing technique, is publicized as a promising tool for curing several genetic diseases and cancers. However, very limited research has been conducted as of now on autoimmune disease management and cure via CRISPR/Cas technique. This review provides an account of the potential candidate genes associated with Hashimoto’s thyroiditis, and only a few animal and human models have been generated via the CRISPR/Cas gene editing technique. Mouse models of autoimmune thyroiditis generated through the CRISPR/Cas gene editing technique by targeting the candidate genes will provide us with a deeper insight into the pathophysiology of HT and further pave the way for the immunomodulation of HT via gene editing.
- 19 October 2023
- Published by Springer Nature in Cell Biochemistry and Biophysics
- Vol. 82 (1) , 91-105
Role of toll-like receptor in the pathogenesis of oral cancer
Toll-like receptors are important molecules of innate immunity. They are known as pattern recognition receptors. They recognise certain molecules known as pathogen-associated molecular pattern on a pathogen and release chemicals that causes inflammation. Toll-like receptors (TLR) help in the removal of the infected cell and thus stop the spread of infection and are being studied for their association with cancer. Oral carcinoma has emerged as a major problem of our country today; it is found ranks first in men and third in women. Toll-like receptors have been implicated in the development of cancer. Certain polymorphisms in toll-like receptor can make a cell more susceptible to develop oral cancer. The identification of toll-like receptors and the different genotypes that are involved in the development of cancer can be utilised for using them as biomarkers of the disease. The study revealed that toll-like receptors like TLR7 and TLR5 are found to have a role in suppression of oral cancer while toll-like receptors like TLR4 and TLR2 are found to be associated with the progression of oral cancer. Toll-like receptors can turn out as important target molecules in the future in designing therapeutic strategies for oral cancer.
- 19 October 2023
- Published by Springer Nature in Cell Biochemistry and Biophysics
- Vol. 82 (1) , 91-105
Role of toll-like receptor in the pathogenesis of oral cancer
Toll-like receptors are important molecules of innate immunity. They are known as pattern recognition receptors. They recognise certain molecules known as pathogen-associated molecular pattern on a pathogen and release chemicals that causes inflammation. Toll-like receptors (TLR) help in the removal of the infected cell and thus stop the spread of infection and are being studied for their association with cancer. Oral carcinoma has emerged as a major problem of our country today; it is found ranks first in men and third in women. Toll-like receptors have been implicated in the development of cancer. Certain polymorphisms in toll-like receptor can make a cell more susceptible to develop oral cancer. The identification of toll-like receptors and the different genotypes that are involved in the development of cancer can be utilised for using them as biomarkers of the disease. The study revealed that toll-like receptors like TLR7 and TLR5 are found to have a role in suppression of oral cancer while toll-like receptors like TLR4 and TLR2 are found to be associated with the progression of oral cancer. Toll-like receptors can turn out as important target molecules in the future in designing therapeutic strategies for oral cancer.